<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">39308515</PMID><DateCompleted><Year>2024</Year><Month>09</Month><Day>23</Day></DateCompleted><DateRevised><Year>2024</Year><Month>09</Month><Day>24</Day></DateRevised><Article PubModel="Electronic-eCollection"><Journal><ISSN IssnType="Electronic">1555-3906</ISSN><JournalIssue CitedMedium="Internet"><Volume>32</Volume><Issue>10</Issue><PubDate><Year>2024</Year></PubDate></JournalIssue><Title>Oncology research</Title><ISOAbbreviation>Oncol Res</ISOAbbreviation></Journal><ArticleTitle>Prostate cancer temporal and regional trends in Brazil.</ArticleTitle><Pagination><StartPage>1565</StartPage><EndPage>1573</EndPage><MedlinePgn>1565-1573</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.32604/or.2024.052179</ELocationID><Abstract><AbstractText Label="OBJECTIVES" NlmCategory="UNASSIGNED">The Brazilian Unified Health System (Sistema Único de Saúde-SUS) is the universal public healthcare system of Brazil that maintains a nationwide database of its patients. Our primary objective was to analyze regional and temporal trends, while our secondary goal was to establish correlations between states' health economy status and their prostate cancer (PCa) epidemiology.</AbstractText><AbstractText Label="METHODS" NlmCategory="UNASSIGNED">We analyzed Brazil's nationwide data on prostate cancer (PCa) incidence, mortality, and care gathered between 2013 and 2021 by the Information Technology Department of SUS (DATA-SUS), updated monthly using the International Classification of Diseases (ICD-10) code.</AbstractText><AbstractText Label="RESULTS" NlmCategory="UNASSIGNED">In the period, 273,933 new cases of PCa and 135,336 PCa deaths were reported in men aged 50 years or over in Brazil. The median annual PCa-specific incidence rate (PCSIR) ranged from 14.7 in the Southeast to 6.9 in the North region and the median annual PCa-specific mortality rate (PCSMR) ranged from 7.7 in the Northeast to 6.0 in the South region (per 10,000 men &gt;50). The median annual mortality to incidence ratio (MIR) was highest in the North (0.88) and lowest in the Southeast region (0.44). There were significant regional differences in PCa treatment rates (per new cases); the Midwest region had the highest median annual surgery rate (0.63) while the North region had the highest median annual systemic therapy rate (0.75) and the lowest radiation therapy rate (0.06). Temporal analysis of the data showed significant change in annual rate trends after the year 2018 for PCSIR (coefficient [<i>β</i>] = +3.66, <i>p</i> &lt; 0.001), any treatment (<i>β</i> = -0.06, <i>p</i> = 0.016), surgery ([SR] <i>β</i> = +0.05, <i>p</i> = 0.017) radiation therapy ([RTR] <i>β</i> = -0.06, <i>p</i> = 0.005) and systemic therapy ([STR] <i>β</i> = -0.10, <i>p</i> = 0.002). After the 2020 pandemic, annual PCSIR decreased (<i>β</i> = -2.15, <i>p</i> = 0.002) but annual PCSMR, MIR, and treatment rates remained stable. Correlation studies showed that the PCSIR was strongly negatively correlated with STR (<i>p</i> &lt; 0.001) and positively correlated with RTR (<i>p</i> = 0.004). MIR was positively correlated with STR (<i>p</i> &lt; 0.001) and negatively correlated with the number of robotic surgical systems per million population (<i>p</i> = 0.003).</AbstractText><AbstractText Label="CONCLUSION" NlmCategory="UNASSIGNED">Our data shows that PCa care is dependent on the region and is likely influenced by access to treatment options. Furthermore, changes after the year 2018 underscore the influence of international guidelines on Brazilian clinicians' decision-making especially concerning population screening which in turn affected incidence and treatment rates. Limitation of our study includes limited patient-related information and data on private practices as well as an unknown impact of traveling patients.</AbstractText><CopyrightInformation>© 2024 The Authors.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Jalalizadeh</LastName><ForeName>Mehrsa</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>UroScience, School of Medical Sciences, State University of Campinas, Campinas, 13083-872, Brazil.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Roesch</LastName><ForeName>Heveline Rayane Moura</ForeName><Initials>HRM</Initials><AffiliationInfo><Affiliation>UroScience, School of Medical Sciences, State University of Campinas, Campinas, 13083-872, Brazil.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Korkes</LastName><ForeName>Fernando</ForeName><Initials>F</Initials><AffiliationInfo><Affiliation>Division of Urology, Faculdade de Medicina do ABC, São Paulo, 09051-040, Brazil.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Dien-Trinh</LastName><ForeName>Quoc</ForeName><Initials>Q</Initials><AffiliationInfo><Affiliation>Division of Urological Surgery and Center for Surgery and Public Health, Brigham and Women's Hospital, Harvard Medical School, Boston, MA 02115, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Reis</LastName><ForeName>Leonardo Oliveira</ForeName><Initials>LO</Initials><AffiliationInfo><Affiliation>UroScience, School of Medical Sciences, State University of Campinas, Campinas, 13083-872, Brazil.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>ImmunOncology, Pontifical Catholic University of Campinas, PUC-Campinas, Campinas, 13087-571, Brazil.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2024</Year><Month>09</Month><Day>18</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Oncol Res</MedlineTA><NlmUniqueID>9208097</NlmUniqueID><ISSNLinking>0965-0407</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001938" MajorTopicYN="N" Type="Geographic">Brazil</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011471" MajorTopicYN="Y">Prostatic Neoplasms</DescriptorName><QualifierName UI="Q000628" MajorTopicYN="N">therapy</QualifierName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName><QualifierName UI="Q000401" MajorTopicYN="N">mortality</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D015994" MajorTopicYN="N">Incidence</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">COVID-19 pandemic</Keyword><Keyword MajorTopicYN="N">Prostate cancer (PCa) epidemiology</Keyword><Keyword MajorTopicYN="N">Regional disparities</Keyword><Keyword MajorTopicYN="N">Screening</Keyword><Keyword MajorTopicYN="N">Temporal trends</Keyword></KeywordList><CoiStatement>The authors declare that they have no conflicts of interest to report regarding the present study.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2024</Year><Month>3</Month><Day>25</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2024</Year><Month>5</Month><Day>27</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2024</Year><Month>9</Month><Day>23</Day><Hour>7</Hour><Minute>30</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2024</Year><Month>9</Month><Day>23</Day><Hour>7</Hour><Minute>29</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2024</Year><Month>9</Month><Day>23</Day><Hour>5</Hour><Minute>34</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2024</Year><Month>9</Month><Day>18</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">39308515</ArticleId><ArticleId IdType="pmc">PMC11413836</ArticleId><ArticleId IdType="doi">10.32604/or.2024.052179</ArticleId><ArticleId IdType="pii">52179</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, et al. . Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2021;71(3):209–49. doi:10.3322/caac.21660;</Citation><ArticleIdList><ArticleId IdType="doi">10.3322/caac.21660</ArticleId><ArticleId IdType="pubmed">33538338</ArticleId></ArticleIdList></Reference><Reference><Citation>Santos MDO, Lima FCDSD, Martins LFL, Oliveira JFP, Almeida LMD, Cancela MDC. Cancer incidence estimate in Brazil, 2023–2025. Rev Bras Cancerol. 2023;69(1):e-213700 (In Portuguese). doi:10.32635/2176-9745.RBC.2023v69n1.3700.</Citation><ArticleIdList><ArticleId IdType="doi">10.32635/2176-9745.RBC.2023v69n1.3700</ArticleId></ArticleIdList></Reference><Reference><Citation>Rakel RE, Rakel DP. Textbook of family medicine. 9th edition. Philadelphia, PA: Elsevier Saunders; 2016.</Citation></Reference><Reference><Citation>Desai MM, Cacciamani GE, Gill K, Zhang J, Liu L, Abreu A, et al. . Trends in incidence of metastatic prostate cancer in the US. JAMA Netw Open. 2022;5(3):e222246. doi:10.1001/jamanetworkopen.2022.2246;</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jamanetworkopen.2022.2246</ArticleId><ArticleId IdType="pmc">PMC9907338</ArticleId><ArticleId IdType="pubmed">35285916</ArticleId></ArticleIdList></Reference><Reference><Citation>Burgess L, Aldrighetti CM, Ghosh A, Niemierko A, Chino F, Huynh MJ, et al. . Association of the USPSTF grade D recommendation against prostate-specific antigen screening with prostate cancer-specific mortality. JAMA Netw Open. 2022;5(5):e2211869. doi:10.1001/jamanetworkopen.2022.11869;</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jamanetworkopen.2022.11869</ArticleId><ArticleId IdType="pmc">PMC9112070</ArticleId><ArticleId IdType="pubmed">35576008</ArticleId></ArticleIdList></Reference><Reference><Citation>Mostafavi Zadeh SM, Tajik F, Gheytanchi E, Kiani J, Ghods R, Madjd Z. COVID-19 pandemic impact on screening and diagnosis of prostate cancer: a systematic review. BMJ Support Palliat Care. 2023;70. doi:10.1136/spcare-2023-004310;</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/spcare-2023-004310</ArticleId><ArticleId IdType="pubmed">37748857</ArticleId></ArticleIdList></Reference><Reference><Citation>Ribeiro CM, Correa FDM, Migowski A. Efeitos de curto prazo da pandemia de COVID-19 na realização de procedimentos de rastreamento, investigação diagnóstica e tratamento do câncer no Brasil: estudo descritivo, 2019–2020. Epidemiol Serv Saúde. 2022;31(1):e2021405. doi:10.1590/s1679-49742022000100010.</Citation><ArticleIdList><ArticleId IdType="doi">10.1590/s1679-49742022000100010</ArticleId><ArticleId IdType="pmc">PMC11346577</ArticleId><ArticleId IdType="pubmed">35262614</ArticleId></ArticleIdList></Reference><Reference><Citation>Health Commission of The People’s Republic of China N. National guidelines for diagnosis and treatment of prostate cancer 2022 in China (English version). Chin J Cancer Res. 2022;34(3):270–88. doi:10.21147/j.issn.1000-9604.2022.03.07;</Citation><ArticleIdList><ArticleId IdType="doi">10.21147/j.issn.1000-9604.2022.03.07</ArticleId><ArticleId IdType="pmc">PMC9273581</ArticleId><ArticleId IdType="pubmed">35873888</ArticleId></ArticleIdList></Reference><Reference><Citation>Zetrini AE, Lip H, Abbasi AZ, Alradwan I, Ahmed T, He C, et al. . Remodeling tumor immune microenvironment by using polymer-lipid-manganese dioxide nanoparticles with radiation therapy to boost immune response of castration-resistant prostate cancer. Research. 2023;6(10260):247. doi:10.34133/research.0247;</Citation><ArticleIdList><ArticleId IdType="doi">10.34133/research.0247</ArticleId><ArticleId IdType="pmc">PMC10546607</ArticleId><ArticleId IdType="pubmed">37795337</ArticleId></ArticleIdList></Reference><Reference><Citation>Paim J, Travassos C, Almeida C, Bahia L, Macinko J. The Brazilian health system: history, advances, and challenges. Lancet. 2011;377(9779):1778–97. doi:10.1016/S0140-6736(11)60054-8;</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0140-6736(11)60054-8</ArticleId><ArticleId IdType="pubmed">21561655</ArticleId></ArticleIdList></Reference><Reference><Citation>Fonseca BDP, Albuquerque PC, Saldanha RDF, Zicker F. Geographic accessibility to cancer treatment in Brazil: a network analysis. Lancet Reg Health Am. 2022;7:100153. doi:10.1016/j.lana.2021.100153;</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.lana.2021.100153</ArticleId><ArticleId IdType="pmc">PMC9903788</ArticleId><ArticleId IdType="pubmed">36777653</ArticleId></ArticleIdList></Reference><Reference><Citation>Asadzadeh Vostakolaei F, Karim-Kos HE, Janssen-Heijnen MLG, Visser O, Verbeek ALM, Kiemeney LALM. The validity of the mortality to incidence ratio as a proxy for site-specific cancer survival. Eur J Public Health. 2011;21(5):573–7. doi:10.1093/eurpub/ckq120;</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/eurpub/ckq120</ArticleId><ArticleId IdType="pubmed">20813895</ArticleId></ArticleIdList></Reference><Reference><Citation>Wilcox RR. Comparing dependent robust correlations. Brit J Math Statis. 2016;69(3):215–24. doi:10.1111/bmsp.12069;</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/bmsp.12069</ArticleId><ArticleId IdType="pubmed">27114391</ArticleId></ArticleIdList></Reference><Reference><Citation>Iman RL, Conover WJ. The use of the rank transform in regression. Technometrics. 1979;21(4):499–509. doi:10.1080/00401706.1979.10489820.</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/00401706.1979.10489820</ArticleId></ArticleIdList></Reference><Reference><Citation>Kim HJ, Fay MP, Feuer EJ, Midthune DN. Permutation tests for join point regression with applications to cancer rates. Statist Med. 2000;19(3):335–51. doi:10.1002/(ISSN)1097-0258.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/(ISSN)1097-0258</ArticleId><ArticleId IdType="pubmed">10649300</ArticleId></ArticleIdList></Reference><Reference><Citation>Pinto R, Valentim R, da Silva LF, de Souza GF, de Moura Santos Lima TGF, de Oliveira CAP, et al. . Use of interrupted time series analysis in understanding the course of the congenital syphilis epidemic in Brazil. Lancet Reg Health Am. 2021;7:100163. doi:10.1016/j.lana.2021.100163;</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.lana.2021.100163</ArticleId><ArticleId IdType="pmc">PMC9903756</ArticleId><ArticleId IdType="pubmed">36777651</ArticleId></ArticleIdList></Reference><Reference><Citation>Patil I. Visualizations with statistical details: the ggstatsplot approach. J Open Source Softw. 2021;6(61):3167. doi:10.21105/joss.03167.</Citation><ArticleIdList><ArticleId IdType="doi">10.21105/joss.03167</ArticleId></ArticleIdList></Reference><Reference><Citation>Wolf AMD, Wender RC, Etzioni RB, Thompson IM, D’Amico AV, Volk RJ, et al. . American cancer society guideline for the early detection of prostate cancer: update 2010. CA Cancer J Clin. 2010;60(2):70–98. doi:10.3322/caac.20066;</Citation><ArticleIdList><ArticleId IdType="doi">10.3322/caac.20066</ArticleId><ArticleId IdType="pubmed">20200110</ArticleId></ArticleIdList></Reference><Reference><Citation>Moyer VA. Screening for prostate cancer: U.S. preventive services task force recommendation statement. Ann Intern Med. 2012;157(2):120. doi:10.7326/0003-4819-157-2-201207170-00459;</Citation><ArticleIdList><ArticleId IdType="doi">10.7326/0003-4819-157-2-201207170-00459</ArticleId><ArticleId IdType="pubmed">22801674</ArticleId></ArticleIdList></Reference><Reference><Citation>US Preventive Services Task Force, Grossman DC, Curry SJ, Owens DK, Bibbins-Domingo K, Caughey AB, et al. . Screening for prostate cancer: US preventive services task force recommendation statement. JAMA. 2018;319(18):1901–13. doi:10.1001/jama.2018.3710;</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jama.2018.3710</ArticleId><ArticleId IdType="pubmed">29801017</ArticleId></ArticleIdList></Reference><Reference><Citation>Wei JT, Barocas D, Carlsson S, Coakley F, Eggener S, Etzioni R, et al. . Early detection of prostate cancer: AUA/SUO guideline part I: prostate cancer screening. J Urol. 2023;210(1):46–53. doi:10.1097/JU.0000000000003491;</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/JU.0000000000003491</ArticleId><ArticleId IdType="pmc">PMC11060750</ArticleId><ArticleId IdType="pubmed">37096582</ArticleId></ArticleIdList></Reference><Reference><Citation>Mottet N, Van Den Bergh RCN, Briers E, Van Den Broeck T, Cumberbatch MG, De Santis M, et al. . EAU-EANM-ESTRO-ESUR-SIOG guidelines on prostate cancer—2020 update. Part 1: screening, diagnosis, and local treatment with curative intent. Eur Urol. 2021;79(2):243–62. doi:10.1016/j.eururo.2020.09.042;</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.eururo.2020.09.042</ArticleId><ArticleId IdType="pubmed">33172724</ArticleId></ArticleIdList></Reference><Reference><Citation>Leapman MS, Wang R, Park H, Yu JB, Sprenkle PC, Cooperberg MR, et al. . Changes in prostate-specific antigen testing relative to the revised us preventive services task force recommendation on prostate cancer screening. JAMA Oncol. 2022;8(1):41–7. doi:10.1001/jamaoncol.2021.5143;</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jamaoncol.2021.5143</ArticleId><ArticleId IdType="pmc">PMC8587214</ArticleId><ArticleId IdType="pubmed">34762100</ArticleId></ArticleIdList></Reference><Reference><Citation>de Atenção à Saúde S, de Atenção Básica D. Primary care notebooks. Series A. Standards and technical manuals. Brazil: Ministério da Saúde; 2010. p. 95
(In Portuguese). http://biblioteca.cofen.gov.br/wp-content/uploads/2016/05/Cadernos-de-Aten%C3%A7%C3%A3o-Prim%C3%A1ria-n-29-rastreamento.pdf. [Accessed 2024].</Citation></Reference><Reference><Citation>Ministério da Saúde, Instituto Nacional de Câncer José Alencar Gomes da Silva (INCA). INCA Newsletter: early Detection. Monitoring Prostate Cancer Control Actions, Report No. 2. Brazil: INCA; 2014. 
(In Portuguese). https://www.inca.gov.br/sites/ufu.sti.inca.local/files//media/document//informativo-deteccao-precoce-2-2014.pdf.</Citation></Reference><Reference><Citation>Cancer of the Prostate-Cancer Stat Facts . SEER. Available from: https://seer.cancer.gov/statfacts/html/prost.html. [Accessed 2024].</Citation></Reference><Reference><Citation>Qian Z, Chen X, Cole AP, Abdollah F, Choueiri TK, Kibel AS, et al. . Changes in prostate-specific antigen screening after the 2018 United States preventive services task force recommendations and through the COVID-19 pandemic. Eur Urol Oncol. 2024;7(1):151–4. doi:10.1016/j.euo.2023.07.007;</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.euo.2023.07.007</ArticleId><ArticleId IdType="pubmed">37487814</ArticleId></ArticleIdList></Reference><Reference><Citation>Iser DA, Cobalchini GR, Oliveira MMD, Teixeira R, Malta DC, Naghavi M, et al. . Prostate cancer mortality in Brazil 1990–2019: geographical distribution and trends. Rev Soc Bras Med Trop. 2022;55(suppl 1):e0277. doi:10.1590/0037-8682-0277-2021;</Citation><ArticleIdList><ArticleId IdType="doi">10.1590/0037-8682-0277-2021</ArticleId><ArticleId IdType="pmc">PMC9020381</ArticleId><ArticleId IdType="pubmed">35107530</ArticleId></ArticleIdList></Reference><Reference><Citation>Altman N, Krzywinski M. Association, correlation and causation. Nat Methods. 2015;12(10):899–900. doi:10.1038/nmeth.3587;</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nmeth.3587</ArticleId><ArticleId IdType="pubmed">26688882</ArticleId></ArticleIdList></Reference><Reference><Citation>McLaughlin PW, Cousins MM, Tsodikov A, Soni PD, Crook JM. Mortality reduction and cumulative excess incidence (CEI) in the prostate-specific antigen (PSA) screening era. Sci Rep. 2024;14(1):5810. doi:10.1038/s41598-024-55859-z;</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41598-024-55859-z</ArticleId><ArticleId IdType="pmc">PMC10925039</ArticleId><ArticleId IdType="pubmed">38461151</ArticleId></ArticleIdList></Reference><Reference><Citation>Cole AP, Herzog P, Iyer HS, Marchese M, Mahal BA, Lipsitz SR, et al. . Racial differences in the treatment and outcomes for prostate cancer in Massachusetts. Cancer. 2021;127(15):2714–23. doi:10.1002/cncr.33564;</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/cncr.33564</ArticleId><ArticleId IdType="pmc">PMC9107927</ArticleId><ArticleId IdType="pubmed">33999405</ArticleId></ArticleIdList></Reference><Reference><Citation>Cancer facts &amp; Figures . 2023. Available from: https://www.cancer.org/research/cancer-facts-statistics/all-cancer-facts-figures/2023-cancer-facts-figures.html. [Accessed 2024].</Citation></Reference></ReferenceList></PubmedData></PubmedArticle>